Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
about
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trialEvaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strainsGenome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatientsReview of Cohort Studies for Mood DisordersThe International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise AlgorithmPharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D studyPharmacogenomics of neuropsychiatric disorders: analysis of genetic variability in 162 identified neuroreceptors using 1000 Genomes Project data.When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D studyTowards the clinical implementation of pharmacogenetics in bipolar disorder.Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stressPharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.Association study of CREB1 with Major Depressive Disorder and related phenotypes.Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment.Pharmacogenomics of suicidal events.Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran.Effects of the A(-115)G variant on CREB1 promoter activity in two brain cell lines: Interactions with gonadal steroids.Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.Pharmacogenetics of antidepressantsCREB1 gene polymorphisms combined with environmental risk factors increase susceptibility to major depressive disorder (MDD).Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect.Insomnia is a risk factor for suicide-what are the next steps?The promise and reality of pharmacogenetics in psychiatryIdentification of a CREB-dependent serotonergic pathway and neuronal circuit regulating foraging behavior in Caenorhabditis elegans: a useful model for mental disorders and their treatments?Genome-wide association study of antidepressant treatment-emergent suicidal ideation.Nightmares and dysfunctional beliefs about sleep mediate the effect of insomnia symptoms on suicidal ideation.Incomplete coverage of candidate genes: a poorly considered bias.Pharmacogenetics studies in STAR*D: strengths, limitations, and resultsAssociation of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participantsPharmacogenomics with antidepressants in the STAR*D study.Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety.Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.Neurotrophin Genes and Antidepressant-Worsening Suicidal Ideation: A Prospective Case-Control Study.Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.Pharmacogenetic considerations in the treatment of psychiatric disorders.Pharmacotherapy and psychotherapy of pediatric depression.Personalized medicine for depression: can we match patients with treatments?Suicidal ideation during antidepressant treatment: do genetic predictors exist?
P2860
Q21245266-D83EBC8D-63E2-421F-B139-6B59E311D766Q24632901-5C9FFC86-689E-4608-8403-612B864A569EQ24650926-DE2BF72A-D8BC-4B8C-87FC-5045530DAA4AQ26744364-3A0094CC-CE82-4F7A-944E-6A1D6C815218Q28066714-BD0EE7F2-FAC7-45BC-A4D9-D18CF8ABD4D2Q28269390-7B6EFBBB-B73D-4934-8487-4440533B08ECQ30863802-0F355ABA-A8E1-4CE9-8DD1-BC6172510A6CQ33459789-96266630-F26B-47DE-A1DA-3A884D11BA35Q33688133-5D53A10C-DFE3-4F5C-AA51-EA41E48E3AEAQ33694233-E146ED30-9EF0-4DAA-8639-A605DE956441Q33730306-FDBBF130-D900-4157-B7C3-A899B89DCAB3Q33750920-6D879EAA-8834-4FFC-BCF4-077D9BC32F85Q33919579-582A3FE9-880A-446C-9C47-8FD87EE0CF67Q33929926-5E9959C3-D753-4FA2-A2E4-7EF454E73DB4Q34066818-7B5A0B59-9F04-44FC-AB25-4472156881FFQ34116007-7C6307F7-0972-4D31-94D2-B0ADCAC818DCQ34122914-EBF78291-645C-4017-B51A-64B7E2D45B4EQ34803025-5B9F3F4E-CA85-480B-9D43-16654F4344A0Q34814994-8A3C31C9-5231-4852-9841-769D35A97F40Q35026088-570F5ACB-5006-4C92-A74D-3313C4CD3C2FQ35144888-64ADECA7-6AF8-4E72-98FD-C5C30EACB5F2Q35148255-5F69F15E-DEF2-4A3F-84BF-9A7BE70B6568Q35169381-C0DDCD96-E87C-4FD7-ADB6-8187745FB67EQ35226451-183C21F7-CAB9-48EB-B08F-E1337BE05A96Q35602800-00616ABD-0EAD-4B75-BC27-33F24699570CQ35679930-9F1D0CD8-171E-402D-872E-81B1DC686C2DQ36530436-BDA25B70-FC4D-41BF-8433-D0CA19FD8D03Q37108126-C805DA7F-4FA2-4E90-A3BB-060E7A9A6127Q37178537-503660ED-80C1-4D17-AD7A-20C5205FFA53Q37196700-80398FBE-4ED7-4433-A941-03CDD0315C3CQ37205961-C409FCD6-CA4B-4289-AC7F-F397268DFE08Q37208599-EEDD96BD-2666-4218-9561-7536B749C11DQ37329171-6687E6A0-8776-491D-863A-484CCDCCE741Q37380865-71C58300-8575-4008-8087-1CFDBF7D91CDQ37472605-6DC960FA-DF0B-49F1-AED6-9EF52C0F378AQ37532496-1B7D4192-B44D-44E7-B0FD-977AB5A88950Q37681573-2A203742-0689-43F6-80D2-234B6766D8FCQ37779801-C2076A82-E36F-400E-A324-56992A06E29CQ37789098-E80C3C22-8EAD-4CE3-A507-DA2CAF6208D2Q37885976-D24F636B-C26E-4C1B-92E3-F7A00C10B507
P2860
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Association between treatment- ...... g protein in the STAR*D study.
@en
Association between treatment- ...... g protein in the STAR*D study.
@nl
type
label
Association between treatment- ...... g protein in the STAR*D study.
@en
Association between treatment- ...... g protein in the STAR*D study.
@nl
prefLabel
Association between treatment- ...... g protein in the STAR*D study.
@en
Association between treatment- ...... g protein in the STAR*D study.
@nl
P2093
P921
P1433
P1476
Association between treatment- ...... ng protein in the STAR*D study
@en
P2093
Jesen Fagerness
Jordan W Smoller
Madhukar H Trivedi
Maurizio Fava
Roy H Perlis
Shaun Purcell
P304
P356
10.1001/ARCHPSYC.64.6.689
P407
P577
2007-06-01T00:00:00Z